Quince Therapeutics - QNCX Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: $8.50
  • Forecasted Upside: 304.76%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 2 Strong Buy Ratings
$2.10
▲ +0.28 (15.38%)

This chart shows the closing price for QNCX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Quince Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QNCX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QNCX

Analyst Price Target is $8.50
▲ +304.76% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Quince Therapeutics in the last 3 months. The average price target is $8.50, with a high forecast of $11.00 and a low forecast of $6.00. The average price target represents a 304.76% upside from the last price of $2.10.

This chart shows the closing price for QNCX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Strong Buy

The current consensus among 4 investment analysts is to buy (strong buy) stock in Quince Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/17/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/15/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/14/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2024
  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2024
  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2024

Latest Recommendations

  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/7/2024Maxim GroupInitiated CoverageBuy$6.00
10/29/2024RODMAN&RENSHAWUpgradeStrong-Buy
10/29/2024Rodman & RenshawInitiated CoverageBuy$11.00
10/22/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
(Data available from 12/8/2019 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2024

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Quince Therapeutics logo
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $2.10
Low: $1.76
High: $2.17

50 Day Range

MA: $1.38
Low: $0.69
High: $2.16

52 Week Range

Now: $2.10
Low: $0.51
High: $2.45

Volume

298,924 shs

Average Volume

330,441 shs

Market Capitalization

$92.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Quince Therapeutics?

The following Wall Street research analysts have issued stock ratings on Quince Therapeutics in the last twelve months: EF Hutton Acquisition Co. I, Maxim Group, Rodman & Renshaw, and RODMAN&RENSHAW.
View the latest analyst ratings for QNCX.

What is the current price target for Quince Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Quince Therapeutics in the last year. Their average twelve-month price target is $8.50, suggesting a possible upside of 304.8%. Rodman & Renshaw has the highest price target set, predicting QNCX will reach $11.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $6.00 for Quince Therapeutics in the next year.
View the latest price targets for QNCX.

What is the current consensus analyst rating for Quince Therapeutics?

Quince Therapeutics currently has 2 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for QNCX.

What other companies compete with Quince Therapeutics?

How do I contact Quince Therapeutics' investor relations team?

Quince Therapeutics' physical mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 910-5717 and its investor relations email address is [email protected]. The official website for Quince Therapeutics is www.quincetx.com. Learn More about contacing Quince Therapeutics investor relations.